A Long-term Extension Study of PCI-32765 (Ibrutinib)

Summary

The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively receiving treatment with ibrutinib, and who continue to benefit from ibrutinib treatment.

Timeline

Start

2013-09-09

Primary completion

2026-12-31

Completion

2030-12-31

Drugs

Indications